Clinical validation of an autoantibody test for lung cancer

Peter Boyle, C.J. Chapman, S. Holdenrieder, A. Murray, Christopher Robertson, W.C. Wood, P. Maddison, G. Healey, G.H. Fairley, A.C. Barnes, J.F.R. Robertson

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Autoantibodies may be present in a variety of underlying cancers several years before tumours can be detected and testing for their presence may allow earlier diagnosis. We report the clinical validation of an autoantibody panel in newly diagnosed patients with lung cancer (LC).
Three cohorts of patients with newly diagnosed LC were identified: group 1 (n = 145), group 2 (n = 241) and group 3 (n = 269). Patients were individually matched by gender, age and smoking history to a control individual with no history of malignant disease. Serum samples were obtained after diagnosis but before any anticancer treatment. Autoantibody levels were measured against a panel of six tumour-related antigens (p53, NY-ESO-1, CAGE, GBU4-5, Annexin 1 and SOX2). Assay sensitivity was tested in relation to demographic variables and cancer type/stage.
The autoantibody panel demonstrated a sensitivity/specificity of 36%/91%, 39%/89% and 37%/90% in groups 1, 2 and 3, respectively, with good reproducibility. There was no significant difference between different LC stages, indicating that the antigens included covered the different types of LC well.
This assay confirms the value of an autoantibody panel as a diagnostic tool and offers a potential system for monitoring patients at high risk of LC.
LanguageEnglish
Pages383-389
Number of pages7
JournalAnnals of Oncology
Volume22
Issue number2
DOIs
Publication statusPublished - 2010

Fingerprint

Autoantibodies
Lung Cancer
Lung Neoplasms
Tumor
Cancer
Annexins
Neoplasms
Smoking
Reproducibility
Physiologic Monitoring
Neoplasm Antigens
Specificity
Early Diagnosis
Diagnostics
History
Demography
Monitoring
Antigens
Sensitivity and Specificity
Testing

Keywords

  • autoantibodies
  • diagnosed patient
  • clinical validation
  • lung cancer

Cite this

Boyle, P., Chapman, C. J., Holdenrieder, S., Murray, A., Robertson, C., Wood, W. C., ... Robertson, J. F. R. (2010). Clinical validation of an autoantibody test for lung cancer. Annals of Oncology, 22(2), 383-389. https://doi.org/10.1093/annonc/mdq361
Boyle, Peter ; Chapman, C.J. ; Holdenrieder, S. ; Murray, A. ; Robertson, Christopher ; Wood, W.C. ; Maddison, P. ; Healey, G. ; Fairley, G.H. ; Barnes, A.C. ; Robertson, J.F.R. / Clinical validation of an autoantibody test for lung cancer. In: Annals of Oncology. 2010 ; Vol. 22, No. 2. pp. 383-389.
@article{2fe061504b2b4eb1866c75b908e88a8c,
title = "Clinical validation of an autoantibody test for lung cancer",
abstract = "Autoantibodies may be present in a variety of underlying cancers several years before tumours can be detected and testing for their presence may allow earlier diagnosis. We report the clinical validation of an autoantibody panel in newly diagnosed patients with lung cancer (LC). Three cohorts of patients with newly diagnosed LC were identified: group 1 (n = 145), group 2 (n = 241) and group 3 (n = 269). Patients were individually matched by gender, age and smoking history to a control individual with no history of malignant disease. Serum samples were obtained after diagnosis but before any anticancer treatment. Autoantibody levels were measured against a panel of six tumour-related antigens (p53, NY-ESO-1, CAGE, GBU4-5, Annexin 1 and SOX2). Assay sensitivity was tested in relation to demographic variables and cancer type/stage. The autoantibody panel demonstrated a sensitivity/specificity of 36{\%}/91{\%}, 39{\%}/89{\%} and 37{\%}/90{\%} in groups 1, 2 and 3, respectively, with good reproducibility. There was no significant difference between different LC stages, indicating that the antigens included covered the different types of LC well. This assay confirms the value of an autoantibody panel as a diagnostic tool and offers a potential system for monitoring patients at high risk of LC.",
keywords = "autoantibodies , diagnosed patient , clinical validation , lung cancer",
author = "Peter Boyle and C.J. Chapman and S. Holdenrieder and A. Murray and Christopher Robertson and W.C. Wood and P. Maddison and G. Healey and G.H. Fairley and A.C. Barnes and J.F.R. Robertson",
year = "2010",
doi = "10.1093/annonc/mdq361",
language = "English",
volume = "22",
pages = "383--389",
journal = "Annals of Oncology",
issn = "1569-8041",
number = "2",

}

Boyle, P, Chapman, CJ, Holdenrieder, S, Murray, A, Robertson, C, Wood, WC, Maddison, P, Healey, G, Fairley, GH, Barnes, AC & Robertson, JFR 2010, 'Clinical validation of an autoantibody test for lung cancer' Annals of Oncology, vol. 22, no. 2, pp. 383-389. https://doi.org/10.1093/annonc/mdq361

Clinical validation of an autoantibody test for lung cancer. / Boyle, Peter; Chapman, C.J.; Holdenrieder, S.; Murray, A.; Robertson, Christopher; Wood, W.C.; Maddison, P.; Healey, G.; Fairley, G.H.; Barnes, A.C. ; Robertson, J.F.R.

In: Annals of Oncology, Vol. 22, No. 2, 2010, p. 383-389.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical validation of an autoantibody test for lung cancer

AU - Boyle, Peter

AU - Chapman, C.J.

AU - Holdenrieder, S.

AU - Murray, A.

AU - Robertson, Christopher

AU - Wood, W.C.

AU - Maddison, P.

AU - Healey, G.

AU - Fairley, G.H.

AU - Barnes, A.C.

AU - Robertson, J.F.R.

PY - 2010

Y1 - 2010

N2 - Autoantibodies may be present in a variety of underlying cancers several years before tumours can be detected and testing for their presence may allow earlier diagnosis. We report the clinical validation of an autoantibody panel in newly diagnosed patients with lung cancer (LC). Three cohorts of patients with newly diagnosed LC were identified: group 1 (n = 145), group 2 (n = 241) and group 3 (n = 269). Patients were individually matched by gender, age and smoking history to a control individual with no history of malignant disease. Serum samples were obtained after diagnosis but before any anticancer treatment. Autoantibody levels were measured against a panel of six tumour-related antigens (p53, NY-ESO-1, CAGE, GBU4-5, Annexin 1 and SOX2). Assay sensitivity was tested in relation to demographic variables and cancer type/stage. The autoantibody panel demonstrated a sensitivity/specificity of 36%/91%, 39%/89% and 37%/90% in groups 1, 2 and 3, respectively, with good reproducibility. There was no significant difference between different LC stages, indicating that the antigens included covered the different types of LC well. This assay confirms the value of an autoantibody panel as a diagnostic tool and offers a potential system for monitoring patients at high risk of LC.

AB - Autoantibodies may be present in a variety of underlying cancers several years before tumours can be detected and testing for their presence may allow earlier diagnosis. We report the clinical validation of an autoantibody panel in newly diagnosed patients with lung cancer (LC). Three cohorts of patients with newly diagnosed LC were identified: group 1 (n = 145), group 2 (n = 241) and group 3 (n = 269). Patients were individually matched by gender, age and smoking history to a control individual with no history of malignant disease. Serum samples were obtained after diagnosis but before any anticancer treatment. Autoantibody levels were measured against a panel of six tumour-related antigens (p53, NY-ESO-1, CAGE, GBU4-5, Annexin 1 and SOX2). Assay sensitivity was tested in relation to demographic variables and cancer type/stage. The autoantibody panel demonstrated a sensitivity/specificity of 36%/91%, 39%/89% and 37%/90% in groups 1, 2 and 3, respectively, with good reproducibility. There was no significant difference between different LC stages, indicating that the antigens included covered the different types of LC well. This assay confirms the value of an autoantibody panel as a diagnostic tool and offers a potential system for monitoring patients at high risk of LC.

KW - autoantibodies

KW - diagnosed patient

KW - clinical validation

KW - lung cancer

UR - http://annonc.oxfordjournals.org/content/early/2010/07/30/annonc.mdq361.full.pdf+html

U2 - 10.1093/annonc/mdq361

DO - 10.1093/annonc/mdq361

M3 - Article

VL - 22

SP - 383

EP - 389

JO - Annals of Oncology

T2 - Annals of Oncology

JF - Annals of Oncology

SN - 1569-8041

IS - 2

ER -

Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, Wood WC et al. Clinical validation of an autoantibody test for lung cancer. Annals of Oncology. 2010;22(2):383-389. https://doi.org/10.1093/annonc/mdq361